Jefferies analyst Laurence Alexander maintains 3M (NYSE:MMM) with a Hold and lowers the price target from $161 to $145.
Galecto Reports Completion Of Enrollment In Phase 1b/2a GULLIVER-2 Trial Of Its GB1211 In LIver Cirrhosis; ‘Top-line results from GULLIVER-2 trial on track for Q4’22’
Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022
Part 1 of GULLIVER-2 trial completed with positive results as previously announced in December 2021
BOSTON, March 29, 2022 (GLOBE NEWSWIRE)
